-
“Community Routes: Access to Mental Health Care” helps uninsured patients access anxiety and depression care by Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and A partnership with Teva Pharmaceuticals.
-
Expanding the donation of medicines for anxiety and depression to seven new states across the country could expand the reach of the program to more than 650,000 uninsured patients through more than 400 eligible clinics.
-
The program provides access to a portfolio of donated anxiety and depression medicines worth more than $17 million. Teva has given $2 million in grants over two years to free charity clinics that care for uninsured patients.
Santa Barbara, CA and Parsippany, NJ May 3, 2023–(BUSINESS WIRE)–Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceutical Industries, Ltd., a U.S. affiliate of Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) Cal’s today announced an expansion of its medical donations. Joined seven new states to facilitate access to health care for uninsured patients seeking treatment for anxiety and depression through the Collaborative Mental Health Access Program.
Through “Community Route: Access to Mental Health Care,” Teva continues to provide $2 million in grants over two years to free charity clinics to provide charity-based, commonly used anxiety and psychiatric care. Make a portfolio of generic medicines available to treat diseases. depression. Medicines are available at free charity clinics and pharmacies within Direct Relief’s network. The annual value of these medicines offered by Teva, as measured by wholesale acquisition costs (WAC), exceeds $17 million this year alone.
This announcement expands the program’s drug donations to seven new states (Alabama, Georgia, Mississippi, North Carolina, South Carolina, Texas and Virginia) through a total of 10 more than 400 eligible free charitable clinics. Increased chances of program reaching over 650,000 uninsured patients. state. The seven new states announced today were selected based on the program’s ability to maximize patient impact. This capacity was determined by assessing unmet needs and the existence of a strong network of free and charitable partner clinics in each state.
The program will launch in June 2022, after which the pilot states of Florida, New Jersey, and California will receive product donations, which will then fund select clinics.
Direct Relief CEO and President Thomas Tighe said: Direct Relief is deeply grateful to her for such leadership and dedication, and is committed to working with NAFC and Teva to provide patients with the resources they need to live happier, healthier lives. We welcome the opportunity to cooperate. ”
Dr. Sven Deslevs, Executive Vice President, North America Commercial, Teva, said: “Teva is committed to the pursuit of health equity and will continue to contribute its expertise and resources to help ensure access to medicines for anxiety and depression.”
NAFC President and CEO Nicole Lamoureux said: of the most vulnerable among us. ”
“Efforts on mental health have remained a priority at our clinic since the pandemic began,” said Fred Bauermeister, executive director of Free Clinic in Simi Valley, California. “These donations will allow us to increase access to medicines to treat anxiety and depression for the uninsured or underinsured members of our community, creating both progress and hope.” was completed.”
One-third of adults in the United States exhibit symptoms of anxiety, depression, or both.1 Specifically, more than 5.5 million adults with mental illness are uninsured, and nearly one-third of all adults with mental illness reported being unable to get the treatment they needed.2 Moreover, as a result of the COVID-19 pandemic, racial minorities had higher rates of depression and anxiety compared with their white counterparts. In fact, he was 15 to 23 times more likely to be depressed in people who identified as Black, Hispanic, or Asian.3
About direct relief
Direct Relief is a humanitarian organization committed to improving the health and lives of people affected by poverty and emergencies, making life-saving medical resources available in the United States and around the world, regardless of politics, religion, or ability to pay. We deliver to communities in need. For more information, please visit https://www.DirectRelief.org.
About the National Association of Free Charity Clinics
The National Association of Free and Charitable Clinics (NAFC) is the only non-profit 501c(3) organization whose mission is dedicated to the problems and needs of underserved people nationwide, serving more than 1,400 clinics. We offer services at our free charity clinic. NAFC has been awarded the Platinum Seal of Transparency by GuideStar and a four-star rating by Charity Navigator. Founded in 2001 and headquartered near Washington, DC, the NAFC works to ensure access to affordable, quality health care for the underserved, and to help all. We aim to be the national voice in promoting quality health care for people. For more information about NAFC, please visit www.nafcclinics.org.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and manufacturing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio of over 3,500 products in almost every therapeutic area. Approximately 200 million people worldwide take Teva medicines every day, and he is served by one of the pharmaceutical industry’s largest and most complex chains of supply. In addition to our established presence in generic medicines, we have significant innovative research and operations that support our growing portfolio of innovative biopharmaceuticals. For more information, please visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is based on management’s current beliefs and expectations, is subject to significant known and unknown risks and uncertainties, and may cause future results. , performance or results that differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “plan,” and “guidance.” , and can be identified using words such as “intend”. ““plan,” “believe,” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that may cause or contribute to such differences include the risks associated with donating medicines through collaborative mental health access programs.Ability to compete in the market, including the ability to develop and commercialize biopharmaceuticals, and competition for innovative medicines, including AUSTEDO®Ajovy® and Copaxone®, our ability to achieve the expected results from our investments in our product pipeline, our ability to develop and commercialize additional medicines, and the effectiveness of our patents and other tools to protect our intellectual property rights. Our large amount of indebtedness. This includes costs and delays resulting from global economic conditions and other macroeconomic developments, the impact of government and societal responses, and the extensive pharmaceutical regulations that we are subject to. Compliance, regulatory and litigation issues, including failure to comply with complex legal and regulatory environments. other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2022 (see section entitled “Risk Factors”). include). Forward-looking statements speak only as of the date they are made, and we may update any forward-looking statements or other information contained herein as a result of new information, future events or otherwise. or under no obligation to correct. You are cautioned not to place undue reliance on these forward-looking statements.
________________________________
1 “Anxiety and Depression”. Centers for Disease Control and Prevention, 2023, https://www.cdc.gov/nchs/covid19/pulse/mental-health.htm
2 “The State of Mental Health in America”. Mental Health America, 2023, https://mhanational.org/issues/state-mental-health-america
3 “The Mental Health Burden of Racial and Ethnic Minorities During the COVID-19 Pandemic.” National Institutes of Health, 2022, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365178/
View source version at businesswire.com: https://www.businesswire.com/news/home/20230503005145/en/
contact address
direct relief
America
Tony Moraine
TMorain@directrelief.org
NAFCUnited States
Kelly Thompson
kerry@nafcclinics.org
Teva
America
Jonathan Baker
Yonatan.Beker@tevapharm.com
(973) 2647378